De invloed van gelijktijdig gebruik van NSAIDs en andere MRP-4 remmers op de nieren bij HIV patiënten die worden behandeld met TDF bevattend antiretroviraal regiems. De NSHIV studie.

Recruiting

• Conditions: Renal dysfunction; proximal tubulopathy; HIV-1

• Registration Number: NL-OMON21361
• Lead Sponsor: Erasmus Medical Center Rotterdam, the Netherlands.

Brief Summary

A

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 600

Inclusion Criteria

>18 years of age.

- HIV-1 positive.

Exclusion Criteria

-Not on a TDF containing ART.

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The following parameter will be assessed in HIV-1 patients on TDF containing cART for at least 12 months. Monthly cumulative defined daily dose (DDD) will be calculated by using WHO definitions (22).<br><br /><br /><br>1. The difference in mean 12 months eGFR change between adult HIV-1 patients on TDF containing cART without reported NSAID/MRP4-i exposure and monthly cumulative DDD NSAID exposure (or other MRP4 inhibitors) per quartile.